Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of VRd vs. VPd as induction in high-risk newly diagnosed myeloma shows VGPR or better in 52% of patients on VRd vs. 90.47% with VPd (p-value 0.003), average OS 27 and 21-months (p=0.801), PFS 27 and 20-months for VRd and VPd.”
“VRd vs. VPd as induction therapy in high-risk newly diagnosed multiple myeloma”
Authors: Chun Yan Li, Long Zhong, Dan Gui Chen, Fu Sheng Yao and Hong Yan.
More posts featuring Robert Orlowski.
